Cara Therapeutics, Inc.

NASDAQ:CARA

4.91 (USD) • At close February 4, 2025
Bedrijfsnaam Cara Therapeutics, Inc.
Symbool CARA
Munteenheid USD
Prijs 4.91
Beurswaarde 22,445,034
Dividendpercentage 0%
52-weken bereik 2.712 - 13.8
Industrie Biotechnology
Sector Healthcare
CEO Mr. Christopher A. Posner
Website https://www.caratherapeutics.com

An error occurred while fetching data.

Over Cara Therapeutics, Inc.

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The

Vergelijkbare Aandelen

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

16.05 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

2.72 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

1.74 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

0.62 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

2.37 USD

Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

VERA

38.07 USD

Immatics N.V. logo

Immatics N.V.

IMTX

5.42 USD

Bionano Genomics, Inc. logo

Bionano Genomics, Inc.

BNGO

5 USD

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

9.3 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

20.91 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)